nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipivefrin—ADRA2A—type 2 diabetes mellitus	0.415	1	CbGaD
Dipivefrin—BCHE—Ramipril—type 2 diabetes mellitus	0.107	0.247	CbGbCtD
Dipivefrin—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.101	0.232	CbGbCtD
Dipivefrin—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0954	0.221	CbGbCtD
Dipivefrin—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0664	0.153	CbGbCtD
Dipivefrin—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0636	0.147	CbGbCtD
Dipivefrin—Epinephrine—ADRB3—type 2 diabetes mellitus	0.00131	0.416	CrCbGaD
Dipivefrin—Stinging—Losartan—type 2 diabetes mellitus	0.00122	0.043	CcSEcCtD
Dipivefrin—Conjunctivitis—Glipizide—type 2 diabetes mellitus	0.00105	0.0369	CcSEcCtD
Dipivefrin—Arrhythmia—Repaglinide—type 2 diabetes mellitus	0.00104	0.0368	CcSEcCtD
Dipivefrin—Hypertension—Repaglinide—type 2 diabetes mellitus	0.000878	0.031	CcSEcCtD
Dipivefrin—Arrhythmia—Glipizide—type 2 diabetes mellitus	0.000863	0.0304	CcSEcCtD
Dipivefrin—Hypertension—Rosiglitazone—type 2 diabetes mellitus	0.00083	0.0293	CcSEcCtD
Dipivefrin—Arrhythmia—Glimepiride—type 2 diabetes mellitus	0.000806	0.0284	CcSEcCtD
Dipivefrin—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.000755	0.0266	CcSEcCtD
Dipivefrin—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.000733	0.0258	CcSEcCtD
Dipivefrin—Arrhythmia—Bromocriptine—type 2 diabetes mellitus	0.000727	0.0256	CcSEcCtD
Dipivefrin—Hypertension—Glipizide—type 2 diabetes mellitus	0.000726	0.0256	CcSEcCtD
Dipivefrin—Conjunctivitis—Gliclazide—type 2 diabetes mellitus	0.000723	0.0255	CcSEcCtD
Dipivefrin—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.000706	0.0249	CcSEcCtD
Dipivefrin—Hypertension—Pioglitazone—type 2 diabetes mellitus	0.000696	0.0245	CcSEcCtD
Dipivefrin—Hypertension—Glimepiride—type 2 diabetes mellitus	0.000678	0.0239	CcSEcCtD
Dipivefrin—Hypertension—Sitagliptin—type 2 diabetes mellitus	0.000676	0.0238	CcSEcCtD
Dipivefrin—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000625	0.022	CcSEcCtD
Dipivefrin—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.000612	0.0216	CcSEcCtD
Dipivefrin—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.000611	0.0216	CcSEcCtD
Dipivefrin—Arrhythmia—Gliclazide—type 2 diabetes mellitus	0.000597	0.021	CcSEcCtD
Dipivefrin—Epinephrine—ADRA2A—type 2 diabetes mellitus	0.000593	0.188	CrCbGaD
Dipivefrin—Pain—Glipizide—type 2 diabetes mellitus	0.000587	0.0207	CcSEcCtD
Dipivefrin—Conjunctivitis—Irbesartan—type 2 diabetes mellitus	0.000571	0.0201	CcSEcCtD
Dipivefrin—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.000564	0.0199	CcSEcCtD
Dipivefrin—Epinephrine—TNF—type 2 diabetes mellitus	0.000562	0.178	CrCbGaD
Dipivefrin—Pain—Sitagliptin—type 2 diabetes mellitus	0.000546	0.0193	CcSEcCtD
Dipivefrin—Conjunctivitis—Losartan—type 2 diabetes mellitus	0.000537	0.0189	CcSEcCtD
Dipivefrin—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000506	0.0178	CcSEcCtD
Dipivefrin—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000502	0.0177	CcSEcCtD
Dipivefrin—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000485	0.0171	CcSEcCtD
Dipivefrin—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000472	0.0166	CcSEcCtD
Dipivefrin—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000471	0.0166	CcSEcCtD
Dipivefrin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000471	0.0166	CcSEcCtD
Dipivefrin—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000463	0.0163	CcSEcCtD
Dipivefrin—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.000461	0.0162	CcSEcCtD
Dipivefrin—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000443	0.0156	CcSEcCtD
Dipivefrin—Hypertension—Metformin—type 2 diabetes mellitus	0.00042	0.0148	CcSEcCtD
Dipivefrin—Epinephrine—CYP1A2—type 2 diabetes mellitus	0.000412	0.131	CrCbGaD
Dipivefrin—Pain—Gliclazide—type 2 diabetes mellitus	0.000406	0.0143	CcSEcCtD
Dipivefrin—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000396	0.014	CcSEcCtD
Dipivefrin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000389	0.0137	CcSEcCtD
Dipivefrin—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.00038	0.0134	CcSEcCtD
Dipivefrin—Pain—Orlistat—type 2 diabetes mellitus	0.000368	0.013	CcSEcCtD
Dipivefrin—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000366	0.0129	CcSEcCtD
Dipivefrin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00035	0.0123	CcSEcCtD
Dipivefrin—Tachycardia—Losartan—type 2 diabetes mellitus	0.000344	0.0121	CcSEcCtD
Dipivefrin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000321	0.0113	CcSEcCtD
Dipivefrin—Pain—Irbesartan—type 2 diabetes mellitus	0.00032	0.0113	CcSEcCtD
Dipivefrin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000317	0.0112	CcSEcCtD
Dipivefrin—Pain—Losartan—type 2 diabetes mellitus	0.000302	0.0106	CcSEcCtD
Dipivefrin—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000295	0.0104	CcSEcCtD
Dipivefrin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000276	0.00973	CcSEcCtD
Dipivefrin—Epinephrine—CYP3A4—type 2 diabetes mellitus	0.000273	0.0866	CrCbGaD
Dipivefrin—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00026	0.00916	CcSEcCtD
Dipivefrin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000223	0.00785	CcSEcCtD
Dipivefrin—ADRA1A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	8.74e-06	7.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	8.68e-06	7.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	8.68e-06	7.17e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.67e-06	7.16e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.64e-06	7.14e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	8.59e-06	7.09e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	8.58e-06	7.09e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—AGT—type 2 diabetes mellitus	8.58e-06	7.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	8.54e-06	7.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—APOB—type 2 diabetes mellitus	8.53e-06	7.04e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	8.51e-06	7.03e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—ALB—type 2 diabetes mellitus	8.49e-06	7.02e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—CALM1—type 2 diabetes mellitus	8.43e-06	6.97e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PPARG—type 2 diabetes mellitus	8.43e-06	6.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.42e-06	6.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—APOE—type 2 diabetes mellitus	8.4e-06	6.94e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—LPL—type 2 diabetes mellitus	8.38e-06	6.92e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	8.34e-06	6.89e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.31e-06	6.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	8.31e-06	6.86e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	8.3e-06	6.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.27e-06	6.83e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—INS—type 2 diabetes mellitus	8.26e-06	6.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.21e-06	6.78e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.16e-06	6.74e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	8.14e-06	6.73e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.12e-06	6.71e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—PIK3R1—type 2 diabetes mellitus	8.12e-06	6.71e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—NOS3—type 2 diabetes mellitus	8.12e-06	6.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	8.12e-06	6.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	8.08e-06	6.67e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	8.05e-06	6.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	7.98e-06	6.59e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—C3—type 2 diabetes mellitus	7.98e-06	6.59e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	7.97e-06	6.59e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	7.97e-06	6.58e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	7.94e-06	6.56e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	7.94e-06	6.56e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.94e-06	6.56e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.91e-06	6.53e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.87e-06	6.5e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.86e-06	6.5e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.79e-06	6.44e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	7.74e-06	6.39e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.72e-06	6.38e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.71e-06	6.37e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.69e-06	6.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	7.68e-06	6.34e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	7.67e-06	6.34e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.64e-06	6.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	7.64e-06	6.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	7.64e-06	6.31e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.61e-06	6.28e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.59e-06	6.27e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—AGT—type 2 diabetes mellitus	7.58e-06	6.26e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—ALB—type 2 diabetes mellitus	7.58e-06	6.26e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.55e-06	6.24e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.55e-06	6.24e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	7.55e-06	6.24e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	7.55e-06	6.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	7.52e-06	6.21e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	7.52e-06	6.21e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.48e-06	6.18e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.45e-06	6.16e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.44e-06	6.14e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—PTGS2—type 2 diabetes mellitus	7.43e-06	6.14e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—APOE—type 2 diabetes mellitus	7.43e-06	6.13e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—LEP—type 2 diabetes mellitus	7.43e-06	6.13e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	7.38e-06	6.09e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.38e-06	6.09e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.34e-06	6.07e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.34e-06	6.06e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	7.33e-06	6.06e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	7.33e-06	6.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	7.32e-06	6.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.31e-06	6.04e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PIK3R1—type 2 diabetes mellitus	7.25e-06	5.99e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—NOS3—type 2 diabetes mellitus	7.25e-06	5.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.24e-06	5.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.2e-06	5.95e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	7.19e-06	5.94e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.18e-06	5.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	7.18e-06	5.93e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.17e-06	5.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	7.17e-06	5.92e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	7.14e-06	5.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	7.13e-06	5.89e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.1e-06	5.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.09e-06	5.86e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.05e-06	5.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	7.03e-06	5.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	7.03e-06	5.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.02e-06	5.8e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7e-06	5.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	6.97e-06	5.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.95e-06	5.74e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.88e-06	5.68e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	6.85e-06	5.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	6.83e-06	5.64e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	6.81e-06	5.62e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.75e-06	5.58e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	6.75e-06	5.57e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.71e-06	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	6.67e-06	5.51e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PTGS2—type 2 diabetes mellitus	6.63e-06	5.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.63e-06	5.47e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.62e-06	5.47e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	6.6e-06	5.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	6.58e-06	5.44e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	6.43e-06	5.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.39e-06	5.28e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—INS—type 2 diabetes mellitus	6.34e-06	5.24e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.32e-06	5.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	6.3e-06	5.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	6.3e-06	5.2e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.29e-06	5.2e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.28e-06	5.19e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.27e-06	5.18e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	6.27e-06	5.18e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.27e-06	5.18e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.24e-06	5.16e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.22e-06	5.13e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.21e-06	5.13e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.18e-06	5.11e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.16e-06	5.09e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	6.14e-06	5.07e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	6.14e-06	5.07e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.14e-06	5.07e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.13e-06	5.07e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	6.13e-06	5.06e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.11e-06	5.04e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.07e-06	5.02e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	6e-06	4.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	5.94e-06	4.91e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.91e-06	4.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.9e-06	4.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.85e-06	4.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.83e-06	4.82e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	5.83e-06	4.82e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.83e-06	4.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	5.82e-06	4.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.81e-06	4.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.8e-06	4.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	5.8e-06	4.79e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.79e-06	4.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.78e-06	4.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	5.76e-06	4.76e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.73e-06	4.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	5.71e-06	4.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	5.71e-06	4.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.64e-06	4.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.64e-06	4.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.64e-06	4.66e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.56e-06	4.6e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.56e-06	4.6e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.51e-06	4.55e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.48e-06	4.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.38e-06	4.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	5.35e-06	4.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	5.3e-06	4.38e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.26e-06	4.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.26e-06	4.35e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	5.25e-06	4.33e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—RELA—type 2 diabetes mellitus	5.24e-06	4.33e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.16e-06	4.27e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	5.11e-06	4.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	5.11e-06	4.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.09e-06	4.21e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.08e-06	4.19e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.07e-06	4.19e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.05e-06	4.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	4.95e-06	4.09e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	4.88e-06	4.03e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.83e-06	3.99e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.82e-06	3.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.8e-06	3.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.78e-06	3.95e-05	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.77e-06	3.94e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.75e-06	3.93e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.72e-06	3.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.72e-06	3.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.71e-06	3.89e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.69e-06	3.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.69e-06	3.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	4.68e-06	3.86e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.6e-06	3.8e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.6e-06	3.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.52e-06	3.74e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.51e-06	3.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.48e-06	3.7e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.47e-06	3.7e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.47e-06	3.69e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.46e-06	3.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.44e-06	3.67e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.42e-06	3.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.38e-06	3.62e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.33e-06	3.58e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.33e-06	3.58e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.28e-06	3.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.28e-06	3.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.22e-06	3.49e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.18e-06	3.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.17e-06	3.44e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—SRC—type 2 diabetes mellitus	4.12e-06	3.4e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.1e-06	3.38e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.06e-06	3.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.02e-06	3.32e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.01e-06	3.31e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.94e-06	3.26e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.91e-06	3.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	3.89e-06	3.22e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.88e-06	3.21e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.79e-06	3.13e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—AKT1—type 2 diabetes mellitus	3.73e-06	3.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.73e-06	3.08e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.69e-06	3.05e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.68e-06	3.04e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.66e-06	3.03e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.65e-06	3.02e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.65e-06	3.02e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.63e-06	3e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.61e-06	2.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.61e-06	2.98e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.58e-06	2.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.48e-06	2.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.43e-06	2.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.41e-06	2.82e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.4e-06	2.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.39e-06	2.8e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—AKT1—type 2 diabetes mellitus	3.33e-06	2.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.33e-06	2.75e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.32e-06	2.74e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.16e-06	2.61e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.08e-06	2.54e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.04e-06	2.51e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.98e-06	2.46e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	2.89e-06	2.39e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.83e-06	2.34e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.81e-06	2.32e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.77e-06	2.29e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.77e-06	2.29e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	2.62e-06	2.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.59e-06	2.14e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.56e-06	2.11e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.42e-06	2e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	2.35e-06	1.94e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.29e-06	1.89e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.13e-06	1.76e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.12e-06	1.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.97e-06	1.62e-05	CbGpPWpGaD
